Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: A novel and sensitive DNA methylation marker for the urine-based liquid biopsies to detect bladder cancer

Fig. 4

A DMRTA2 methylation in SV-HUC-1 and various BC cell lines detected by MSP. MSP products in lanes U and M indicate the presence of unmethylated and methylated DMRTA2, respectively. B Quantification of mDMRTA2 in SV-HUC-1 and various BC cell lines by qMSP with ACTB as the reference gene. Data is shown as mean ± s.d. of three independent experiments (n = 3). C Level of DMRTA2 mRNA expression in SV-HUC-1 and various BC cell lines by RT-qPCR with GAPDH as the reference gene. Data is shown as mean ± s.d. of three independent experiments (n = 3). (D) Elevation of DMRTA2 mRNA expression in SV-HUC-1 and various BC cell lines after 5’-Aza-dC treatment (demethylation) by RT-qPCR with GAPDH as the reference gene. Data is shown as mean ± s.d. of three independent experiments (n = 3). E and F, Level of DMRTA2 protein expression detected in SV-HUC-1 and various BC cell lines by western blot analysis with GAPDH as the internal control. Data is shown as mean ± s.d. of three independent experiments (n = 3). G and H, Effect of 5’-Aza-dC treatment (demethylation) on DMRTA2 expression in the same set of cell lines by western blot analysis. Data shown as mean ± s.d. of three independent experiments (n = 3). I and J, Examination of DMRTA2 expression in BC and adjacent normal tissues by IHC. Left panel and right panel show negative and positive staining for two distinct tissue sections. K and L, Morphological features of tumor and adjacent normal tissue sections revealed by H&E staining. Scale bar is 100 μm. Paired t test was used to analyze statistical significance for experiments with 5’-Aza-dC treatment. Independent t test was used for all other experiments. *p < 0.05 and **p < 0.01

Back to article page